Aerami Therapeutics
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2520 Meridian Pkwy Ste 400, Durham, Nort...Phone Number
(646) 627-8387Website
www.aerami.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Aerami Therapeutics
Aerami Therapeutics Holdings, Inc. is focused on developing inhaled medications to treat serious and rare cardiopulmonary diseases, particularly pulmonary hypertension. The company's mission is to improve patients' quality of life by creating advanced drug-device combination products, such as AER-901, which effectively deliver therapies deep into lung tissues. Their innovative approach includes a smart nebulizer that provides real-time feedback to optimize treatment delivery. Aerami primarily targets patients suffering from unmet medical needs associated with pulmonary hypertension.Explore more
Aerami Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aerami Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Aerami Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Aerami Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Aerami Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Aerami Therapeutics
Click to see if Aerami Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Aerami Therapeutics is spiking on competitors!
Aerami Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Aerami Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Aerami Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Aerami Therapeutics
Compare insights from companies similar to Aerami Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aerami Therapeutics
<$5M
11-50
Private
$88.3M
2010
CH
Christie HudsonSenior Director, Clinical Operations
<$5M
1-10
Private
<$5M
2010
RK
Raj KewalramaniSenior VP, Product Development Manufacturing (Drug & Device)
Company Profile Activity
Activity Insights
Aerami Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aerami Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aerami Therapeutics.
Aerami Therapeutics financials insights
Gather financial insights about Aerami Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$5.1M
2015
Multiple Rounds
$39.6M
2016
Private Equity
$625K
2017
Private Equity
$3.4M
Private Equity
$19M
2019
Unspecified
$20.5M
Aerami Therapeutics Tech Stack
A closer look at the technologies used by Aerami Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
New Hire
Executive Move
Sarah Fritchley has assumed the role of Senior VP, Clinical Development & Operations. Previously, Fritchley served as Chief Development Officer at Exvastat.
New Hire
Executive Move
Aerami Therapeutics News & Media
Aerami Therapeutics to Present New Lung Deposition Modeling Data for AER-901, in Development for Pulmonary Hypertension, at the American Thoracic Society 2024 International Conference
DURHAM, N.C., May 08, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary diseases, today announced presentations related to AER-901, a proprietary liquid formulation of imatinib for inhalation administered via high-performance, handheld, smart nebulizer, at the upcoming American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in SAerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension
DURHAM, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary conditions, today announced new additions to its management team as the company prepares for the imminent initiation of the planned “uniPHied” Phase 2 trial of AER-901 (inhaled imatinib), in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertAerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension
DURHAM, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary conditions, today announced results from studies of AER-901 (inhaled imatinib) that support progression into a Phase 2 clinical trial in both pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary conditions, today announced that non-clinical pharmacokinetic data and details of the completed AER-901 Phase 1 trial in healthy volunteers will be presented at the 2023 American Thoracic Society (ATS) International Conference, being held at the Walter E. Washington Convention Center in Washing
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Aerami Therapeutics
Sign Up For FreeTo access detailed company insights
Aerami Therapeutics Holdings, Inc. is focused on developing inhaled medications to treat serious and rare cardiopulmonary diseases, particularly pulmonary hypertension. The company's mission is to improve patients' quality of life by creating advanced drug-device combination products, such as AER-901, which effectively deliver therapies deep into l... Read More
